Evidence map›Paper›PMID 31399867›Full record

ArticleMedical oncology (Northwood, London, England)2019

MicroRNA expression profiling provides novel insights into immune-related pathways involved in gastric cancer.

Mário Rino Martins, Renata Santos Almeida, Norma Lucena-Silva, Cláudia Malheiros Coutinho-Camilo, Israel Torjal, Rogério Luiz Dos Santos, Cristiana Libardi Miranda-Furtado, Álvaro Fabrício Lopes Rios, Leuridan Cavalcante Torres, Maria Dirlei F S Begnami

Abstract read
PubMed Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. MicroRNA-4290 suppresses PDK1-mediated glycolysis to enhance the sensitivity of gastric cancer cell to cisplatin.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2020
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 1 country.

Mário Rino MartinsOncology Surgical Department, Sociedade Pernambucana de Combate ao Câncer - Hospital do Câncer de Pernambuco, Recife, Brazil. mario_rino@hotmail.com.
Renata Santos AlmeidaAggeu Magalhães Institute/Oswaldo Cruz Foundation, Recife, Brazil.
Norma Lucena-SilvaAggeu Magalhães Institute/Oswaldo Cruz Foundation, Recife, Brazil.
Cláudia Malheiros Coutinho-CamiloInternational Research Center, A.C. Camargo Cancer Center, São Paulo, Brazil.
Israel TorjalInternational Research Center, A.C. Camargo Cancer Center, São Paulo, Brazil.
Rogério Luiz Dos SantosOncology Surgical Department, Sociedade Pernambucana de Combate ao Câncer - Hospital do Câncer de Pernambuco, Recife, Brazil.
Cristiana Libardi Miranda-FurtadoDrug Research and Development Center, Postgraduate Program in Medical and Surgical Science, Federal University of Ceará, Fortaleza, Brazil.
Álvaro Fabrício Lopes RiosCenter of Bioscience and Biotechnology, State University of North Fluminense Darcy Ribeiro, Rio de Janeiro, Brazil.
Leuridan Cavalcante TorresTranslational Research Laboratory Prof. C.A. Hart, Instituto de Medicina Integral Prof. Fernando Figueira (IMIP), Recife, Brazil.
Maria Dirlei F S BegnamiAnatomic Pathology Department, A.C. Camargo Cancer Center, São Paulo, Brazil.
AC Camargo Hospital · BRFundação Oswaldo Cruz · BRHospital de Câncer de Pernambuco · BRInstituto de Medicina Integral Professor Fernando Figueira · BRState University of Norte Fluminense · BRUniversidade Federal do Ceará · BR

Funding

FAPESP - from Fundação de amparo à pesquisa do Estado de São Paulo 12/12551-9
6 · The paper itself

Abstract

Gastric cancer is one of the most common cancers, and an increasing number of studies have found that microRNAs (miRNAs) play essential roles in gastric cancer progression; however, the roles of specific miRNAs involved in the immune response to this disease remain unclear. We compared the miRNA expression in tissues from primary gastric cancer patients and healthy controls to find miRNAs dysregulated in gastric cancer and used bioinformatics tools to determine potential roles of these miRNAs in the immune system. We evaluated 25 primary gastric cancer tissues and five healthy gastric tissues. Quantitative real-time polymerase chain reaction was performed for a set of miRNAs, followed by the prediction of their target genes and functional enrichment analysis of these targets. Analysis of a microarray dataset showed that the miRNA miR-196a-5p was significantly upregulated, while miR-374a-5p and miR-375 were downregulated in gastric cancer patients. In addition, miR-374-5p was significantly downregulated in patients with metastasis compared with its expression levels in non-metastatic patients (p = 0.03). Bioinformatics analysis suggested that the pathways regulated by these differentially expressed miRNAs were related to the immune response, cell adhesion, and cell migration. Most importantly, this study provides a new insight into the potential use of multiple miRNAs to find distinct pathways of immune regulation in gastric cancer.

Indexed as

AdultAgedAged, 80 and overBiomarkers, TumorComputational BiologyFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticGenes, NeoplasmHumansMaleMicroRNAsMiddle AgedNeoplasm MetastasisSignal TransductionStomachBiomarkers, TumorMicroRNAsBioinformaticsGastric cancerImmune systemMicroarray analysisMicroRNA

Identifiers

PMID31399867
OpenAlexW2968214600

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.